MEBO International

What MEBO International does

MEBO International is a privately held Chinese-headquartered regenerative life science company founded in 1987, operating under the legal name MEBO Group. The company is built around Human Body Regenerative Restoration Science (HBRRS), a proprietary platform that activates Potentially Regenerative Cells (PRCs) in situ to regenerate damaged tissues and organs without transplantation. Its foundational technology, MEBT/MEBO (Moist Exposed Burn Therapy combined with Moist Exposed Burn Ointment), was invented by founder Dr. Rongxiang Xu in 1988 and was the first approved new drug under the Pharmaceutical Administration Law of P.R.C. The portfolio spans pharmaceutical products for burns, wounds, and ulcers; oral regenerative nutritional substances for gastrointestinal and cancer supportive care; cosmetics and skincare for regenerative rejuvenation; and medical devices such as wound dressings.

The company monetizes through a diversified revenue model including one-time-license pharmaceutical and consumer health product sales, plus professional services from clinical training and treatment delivery. Go-to-market combines enterprise field sales into hospitals with channel partnerships (Clinton Global Initiative, UN programs, Belt and Road Initiative training) and event-driven academic platforms such as the International Society of Regenerative Medicine and Wound Repair (ISRMWR). Named institutional research partners include Harvard Medical School Beth Israel Deaconess Medical Center, USC Davis School of Gerontology, and California State University Los Angeles, where MEBO has endowed permanent centers and colleges. Following Dr. Xu's death in April 2015, leadership passed to Kevin Xu, and the company has continued to expand its footprint across 110+ countries with claimed treatment of 40 million patients and an IP portfolio exceeding 100 international patents.

Operating geographies span China, the United States, Korea, Russia, India, Thailand, and Malaysia, with active European expansion via the Bay Area Council partnership. Revenue is not publicly disclosed, and the reported 1-10 employee count is inconsistent with the breadth of operations, suggesting the data reflects a single legal entity rather than the consolidated group. The company operates as a founder-controlled private enterprise with no disclosed funding rounds, M&A activity, or regulatory actions.

Name

MEBO International

Legal name

MEBO Group

Website

http://en.mebo.com/

Company type

Private

Founded year

1987

Operating status

Operating

Headcount range

1–10 employees

Short description

MEBO International is a privately held Chinese-headquartered regenerative life science company founded in 1987 that develops and commercializes HBRRS-based pharmaceutical, nutritional, cosmetic, and medical device products for hospitals and medical professionals across 110+ countries, anchored by proprietary PRC activation technology.

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

akta.pro secondary industries

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Regenerative medicine
• Burn treatment products
• Wound healing therapy
• Gastrointestinal regeneration
• Regenerative skincare

Headquarters

HQ city

Changyang

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Pharmaceutical Products: Dozens of regenerative pharmaceutical products with independent intellectual property including drugs for burns, wounds, ulcers, and gastrointestinal regeneration.
2. Healthcare Products and Nutritional Supplements: Regenerative nutritional substances and health food products for oral delivery supporting gastrointestinal regeneration and regenerative nourishment, including cancer supportive care.
3. Cosmetics and Skincare Products: Cosmetics and skincare products for skin functional repair and regenerative rejuvenation with proprietary regenerative technology.
4. Medical Devices: Medical devices for regenerative medical technology including wound dressings and tissue engineering products.
5. Clinical Treatment Services: Regenerative medical technology clinical treatment services through trained hospital networks, including training of doctors on standard application of regenerative medical technology.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

MEBO International develops, manufactures, and distributes a portfolio of regenerative medicine products based on its proprietary Human Body Regenerative Restoration Science (HBRRS). Its core offerings include the MEBT/MEBO therapeutic system for burns, wounds, and ulcers; MEBO Wound Ointment and Wound Dressing; MEBO Regenerative Nutrients for oral regenerative nourishment; gastrointestinal regeneration products; and skin functional repair products. The company also delivers clinical treatment services through hospital training networks across more than 110 countries.

Product overview

MEBO International is a regenerative life science company that offers a comprehensive portfolio of regenerative medicine products and therapies. The core offerings include MEBT/MEBO (Moist Exposed Burn Therapy combined with Moist Exposed Burn Ointment), a patented therapeutic system for burns, wounds, and ulcers; MEBO Wound Ointment and Wound Dressing for topical treatment; MEBO Regenerative Nutrients for oral delivery supporting internal organ regeneration; and specialized gastrointestinal and skin care products. The company operates on a platform-plus-modules architecture with the underlying HBRRS (Human Body Regenerative Restoration Science) technology supporting multiple product lines including drugs, healthcare products, nutritional supplements, cosmetics and medical devices.

Differentiator

Problem solved

Functional benefit

Products and services

• MEBO Wound Ointment (Moist Exposed Burn Ointment) A patented botanical drug consisting of multiple botanic components and animal nutritional ingredients with a unique sponge-like frame structure dosage form for treating burns, wounds, and ulcers through skin organ regeneration. Designed for hospitals, burn centers, and medical professionals.
• MEBO Wound Dressing A man-made dressing with MEBO Wound Ointment fully impregnated into the mesh of sterile dry gauze for wound treatment. Designed for hospitals, burn centers, and medical professionals managing burns, wounds, and ulcers.
• MEBT (Moist Exposed Burn Therapy) An innovative therapeutic system for treating damaged tissue organs in skin by potentiating and stimulating Potentially Regenerative Cells and Stem Cells in situ, enabling direct tissue repair and regeneration without transplantation. Applied by trained medical professionals in hospitals and clinical settings.
• MEBO Regenerative Nutrients Oral nutritional formulations designed to promote and sustain orderly proliferation and differentiation of Potentially Regenerative Cells for regenerative nourishment and organ restoration. Also used as adjunctive support for cancer patients.
• MEBO Gastrointestinal Regeneration Products Oral delivery products formulated for maintaining integrity or repairing/regenerating mucosal tissue in the gastrointestinal tract without scar formation. Used by gastroenterologists and medical professionals for treating peptic ulcers, duodenal ulcers, erosive gastritis, and chronic GI diseases.
• MEBO Skin Care/Functional Repair Products Topical agents containing regenerative nutrients in isotonic formulations for restoring normal skin structure and function compromised due to aging. Targeted at adult consumers seeking regenerative rejuvenation of aged skin.

Quantifiable outcome

• 40 million patients cured using regenerative medical technology
• +6 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Eleven partnerships are on record, tiered major, core and regional.

• Bay Area CouncilmajorStrategic or Co-development Partner · 1 April 2026Long-term partnership for transatlantic innovation and investment dialogue. MEBO participates in EU Innovation and Investment Agenda events and has established training networks and medical cooperation platforms across European countries through initiatives like CGI 'Mending European'.
• International Society of Regenerative Medicine and Wound Repair (ISRMWR)coreStrategic or Co-development Partner · 27 February 2018Borderless platform for medical professionals, doctors, researchers, and other sectors dedicated to development and promotion of regenerative life science and medicine. Established in the State Capitol of California in Sacramento, USA. Co-founded by young entrepreneur Kevin Xu with support from California Institute of Regenerative Medicine (CIRM) and Harvard Medical School BIDMC Rongxiang Xu Center.
• Belt and Road Initiative CountriesregionalChannel Partner/ Reseller/ Distributor · 1 April 2017MEBO's Belt and Road Training Platform provides Moist Exposed Burn Therapy Training in countries along Belt and Road initiative including Indonesia, helping train medical workers with simple, practical and effective regenerative treatment.
• United Nations Academic Impact (UNAI)majorGTM or Marketing Partner · 1 July 2016Beijing Rongxiang Regenerative Medicine Research Laboratory became member of UNAI, aligning with UN global education and academic initiatives.
• United Nations Every Woman Every Child InitiativemajorGTM or Marketing Partner · 1 May 2016MEBO International joined UN Every Woman Every Child China Partnership Network and set up first rescue team with regenerative medical technology for UN program. In June 2017, launched five-year 'Life Regeneration' action plan for women and children in Asia and Africa.
• California State University Los Angeles (Calstate LA)majorStrategic or Co-development Partner · 1 January 2016Calstate LA named its biggest college permanently as Rongxiang Xu College of Health and Human Services and established Rongxiang Xu Bioscience Innovation Center in June 2016 - first time in Calstate LA history to name a college after a person.
• Great Hall of the People (China)majorStrategic or Co-development Partner · 1 January 2016Global Conference for Collaboration and Development on Regenerative Life Science convened in Great Hall of the People in January 2016, laying foundation for promoting sustainable development of regenerative life science.
• Clinton Global InitiativemajorGTM or Marketing Partner · 1 September 2015MEBO International commitment 'From Urban to Rural: Training Doctors on Moist Exposed Burn Therapy' providing regenerative medical technology training for 20,000 doctors in China.
• Beth Israel Deaconess Medical Center of Harvard Medical SchoolcoreStrategic or Co-development Partner · 1 January 2015Global cooperative research base of regenerative medical technology providing supports for research, education and clinical practices of regenerative medical technology. Home to Rongxiang Xu MD Center for Regenerative Therapeutics established in December 2015.
• USC Davis School of GerontologycoreStrategic or Co-development Partner · 1 January 2015Global cooperative research base of regenerative life technology providing innovative research and evaluation on regenerative medicine, tissue engineering and regenerative life science. Home to Rongxiang Xu Center of Regenerative Life Science.
• California Institute for Regenerative Medicine (CIRM)coreStrategic or Co-development PartnerCIRM provided support for establishment of the International Society of Regenerative Medicine and Wound Repair (ISRMWR).

Scale indicators6 records

Recent moves10 records

Expansion highlights5 records

Broad incumbents

• Smith+Nephew: Global medical device company with a significant Advanced Wound Management portfolio. Comparable because it serves the same burn, wound, and ulcer treatment markets that MEBO targets with MEBT/MEBO, but at much larger scale with FDA-cleared products.
• Mölnlycke Health Care: Leading global provider of wound care and surgical solutions, including Mepitel, Mepilex, and other advanced wound dressings. Directly comparable in the burn and chronic wound care segment where MEBO's ointment competes.
• Integra LifeSciences: Medical technology company with a strong regenerative tissue technologies portfolio (Integra Dermal Regeneration Template). Comparable in skin regeneration and wound healing applications where MEBO competes.
• ConvaTec Group: Global medical products company specializing in wound care, ostomy, and continence care with brands like AQUACEL. Comparable in advanced wound dressings and burn treatment markets where MEBO competes.
• Coloplast: Global leader in wound care, ostomy, and continence products. Comparable as an established competitor in advanced wound care distribution channels where MEBO seeks hospital adoption.

Direct peers

• Organogenesis Holdings: Commercial-stage regenerative medicine company specializing in skin and wound care products including Apligraf and Dermagraft. Directly comparable as both companies pursue in situ tissue regeneration for skin wounds and ulcers.
• MiMedx Group: Regenerative medicine company using placental tissue allografts for wound care and surgical recovery. Comparable to MEBO as both pursue regenerative approaches to skin and soft tissue repair in hospital settings.
• Vericel Corporation: Commercial-stage cell therapy company with products like MACI (cartilage repair) and Epicel (burn treatment). Comparable to MEBO in autologous cell-based regenerative approaches for burn and wound repair.
• Osiris Therapeutics (Smith+Nephew): Stem cell therapy company (acquired by Smith+Nephew) with Grafix and OvationOS for wound healing. Comparable to MEBO's PRC-based regenerative approach for chronic wounds.

Emerging players

• PolarityTE: Regenerative medicine company developing autologous skin regeneration products. Comparable to MEBO as a smaller, science-driven peer pursuing novel skin and tissue regeneration approaches.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MEBO International